BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 6, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2018

View Archived Issues

Enrollment ongoing in phase II/III trial of indoximod plus pembrolizumab or nivolumab in melanoma

Read More

Roswell Park Cancer Institute and NCI begin phase I trial of sirolimus plus vaccine therapy

Read More

Tosk set to begin proof-of-concept studies of TK-90

Read More

Generation Bio launches

Read More

Rocket and Inotek complete merger

Read More

Gossamer Bio launches with USD 100 million financing

Read More

Jiangsu Hengrui Medicine grants SHR-0302 rights to Arcutis for dermatology disorders

Read More

Stemline presents phase I/II data on SL-401 for myeloproliferative neoplasms

Read More

EMA gives orphan drug designation to Spruce Biosciences' SPR-001

Read More

Peregrine Pharmaceuticals changes name to Avid Bioservices

Read More

Momenta Pharmaceuticals announces topline data from phase I study of M-281

Read More

Northwestern University describes novel nitric oxide synthase inhibitors

Read More

MAKO study of squalamine with Lucentis in wet AMD misses primary endpoint

Read More

Institute of Organic Chemistry and Biochemistry and others patent 17-beta-HSD inhibitors

Read More

EMA accepts Evenity MAA in osteoporosis

Read More

New farnesoid X receptor modulators identified at Gilead

Read More

Alnylam and Sanofi to restructure RNAi therapeutics alliance

Read More

Rice University presents novel thailanstatin A derivatives

Read More

Cadent Therapeutics discovers new potassium channel modulators

Read More

FDA approves sBLA for Amgen's Xgeva

Read More

Final draft guidance by U.K.'s NICE recommends use of Strimvelis for ADA-SCID

Read More

Celgene agrees to acquire Impact Biomedicines

Read More

Rebiotix announces results of analysis of microbiome drug candidates

Read More

ADAR1-targeted therapy could ameliorate multiple myeloma patient outcomes

Read More

Takeda and Denali enter option and collaboration agreement in neurodegenerative diseases

Read More

Kala announces NDA acceptance for KPI-121 1%, phase III data for KPI-121 0.25%

Read More

Experiments reveal the potential of antibiotics for the treatment for colorectal cancer

Read More

Enanta conducts first-in-human study of EDP-938

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing